Prywatna Praktyka Lekarska Prof. dr hab. med. Pawel Hrycaj
- Address
- Os. Rzeczypospolitej 6/202, 61-397 Poznan, Poland
Immune System Diseases Research
At the Poznan‑based private practice, investigators are exploring a targeted therapy for Sjögren’s syndrome, an autoimmune disorder that affects moisture‑producing glands. The study seeks to demonstrate that the experimental antibody ianalumab leads to a meaningful reduction in disease activity, as measured by the ESSDAI scoring system, while also confirming its safety profile.
- Comparison of ianalumab with placebo on ESSDAI score
- Assessment of treatment‑related adverse events
- Evaluation of patient‑reported outcomes over 48 weeks
The site, located at Os. Rzeczypospolitej 6/202 in Poznan, currently supports three clinical trials and provides a focused environment for advancing therapies in immune‑mediated conditions.
Musculoskeletal Diseases Research
Researchers at the same practice are conducting multiple studies on psoriatic arthritis, a chronic inflammatory disease of the joints and skin. The trials evaluate the oral agent zasocitinib in patients who have not previously received biologic medicines, aiming to confirm its effectiveness in reducing joint inflammation and to monitor long‑term safety and tolerability.
- Efficacy of zasocitinib versus placebo in biologic‑naïve patients
- Dose‑response analysis of two dosage levels
- Extended safety monitoring in a long‑term extension study
With a total of three active trials, the centre in Poznan offers participants access to innovative treatments for musculoskeletal disorders while contributing valuable data to the field.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Prywatna Praktyka Lekarska Prof. dr hab. med. Pawel Hrycaj
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Zasocitinib (TAK-279) Versus Apremilast and Placebo in Biologic-Naïve Adults with Active Psoriatic Arthritis | Takeda Development Center Americas Inc. | Phase III | Recruiting | Jun 2025 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 2 | Unknown | 2025-06-26 | 2026-06-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.